Cardiac Function
-
Vutrisiran Improves Cardiac Structure and Function in ATTR-CM Patients: New Post Hoc Analysis of HELIOS-B Phase 3 Trial
New data presented at AHA 2025 from the HELIOS-B study highlights the potential of vutrisiran (AMVUTTRA) in treating transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). CMR analysis showed amyloid regression in 22% of vutrisiran-treated patients. Vutrisiran also preserved kidney function and reduced cardiovascular events, particularly in patients with advanced chronic kidney disease. These findings support AMVUTTRA’s potential as a first-line treatment for ATTR-CM, indicating its ability to impact cardiac structure and function, and offer benefits across multiple affected organs.
